A report by ARC estimated that the plasmid DNA manufacturing market will surpass $300 million by 2026, representing an average annual growth rate of 20 percent from 2019 to 2026.

There are continuous development activities carried by major players in order to test plasmid DNA applicability. Usually plasmid DNA is prepared by cesium chloride density ultracentrifugation process and it has wide applications such as clones screening, sequencing, restriction digestion, cloning, and PCR.  Plasmid DNA can be purified by various technique but most it is purified by using bacteria technique. These techniques include various methods such as alkaline lysis and ammonium acetate precipitation, and ion-exchange columns such as Qiagen columns, cesium chloride gradient separation, or PEG precipitation methods. Aldevron, Cobra Biologics Limited, Delphi Genetics, and VGXI, Inc., are some of the major manufacturers involved in manufacturing of the plasmid DNA.

Request Free Sample Report Pages for Better Understanding, Download Here

Rapid technological advancements in the healthcare sector, rising prevalence of chronic diseases and genetic disorders across the globe, and increasing R&D activities by major players on gene therapy are some major factors expected to drive the growth of global market. In addition, rising government expenditure on the healthcare sector, coupled with growing clinical trials for development of various vaccinations are among other factors that are expected to support the growth of global plasmid DNA manufacturing market to a certain extent.

The adoption of gene therapy is expected to be limited by complications such as risk of mutagenesis, safety & efficacy issues and strict regulatory framework, which will impede the market growth. DNA damage caused by a chemical in a cell is an important first step in the process. Several mechanisms for repair of DNA have evolved in order to cure the damage caused by DNA, but each cannot repair, especially if the damage is caused at a high rate. The replication of damaged DNA increases the rate of polymerase errors, leading to gene mutations that can lead to altered protein synthesization. Oncogene mutations, a tumor-suppressor gene or a gene controlled by cells may give rise to a population of clonal cells with a clear propagating advantage. Many such events, occurring in the context of chronic exposure to chemical mutagens over a long time, can lead to human cancer.

Nevertheless, factors that are expected to create new opportunities in terms of revenue for players operating in the target market over the forecast period include increasing healthcare spending and developing regulatory standards in developing countries. In addition, manufacturers’ approach towards expansion in developing countries, owing to availability of required healthcare infrastructure in order to conduct R&D activities is another factor expected to support the market growth.

Segment Overview:

Gene therapy accounts for the largest share of global plasmid DNA manufacturing market. The main attribution is that gene therapy products are increasingly accepted in the treatment of rare disorders around the globe. Gene therapy is a promising therapeutic modality for the treatment of inherited as well as acquired genetic disorders. Gene medicines have emerged as a potentially safe and effective gene therapy method for the treatment of a wide variety of acquired and inherited disorders.

Regional Insights

The market in North America is expected to contribute major revenue share in the global plasmid DNA manufacturing market. The market for plasmid DNA manufacturing in North America is driven by rapid technological advancements and R&D activities in the healthcare sector. In addition, presence of several biopharmaceutical manufacturers in the US coupled with a strong and effective regulatory structure for development of advanced therapies in the country is boosting the growth of this market in North America. Besides this, recent approval of gene therapies by US FDA is projected to augment the demand for plasmid DNA manufacturing in coming years.

The market in Asia Pacific is expected to witness faster growth in the global plasmid DNA manufacturing market. This can be attributed to the increasing government expenditure on development of healthcare infrastructure in the region. In addition, the growing government initiatives and increased investments by private companies related to R&D activities are likely to fuel this regional market.

Europe is expected to witness substantial growth in the market for plasmid DNA manufacturing. Factors that are expected to drive the growth in European market are significant incentives offered through Orphan Medicinal Products Regulations (European Union) that has encouraged pharmaceutical and biotechnology companies to consider the development of rare disease medicines as a potentially profitable endeavor.

Some of the key players operating in the global plasmid DNA manufacturing market, profiled in the report include Aldevron, Cobra Biologics Limited, Delphi Genetics, VGXI, Inc., PlasmidFactory GmbH & Co. KG, LakePharma, Inc., Akron Biotech, Waisman Biomanufacturing, Richter-Helm BioLogics, Eurogentec, Kaneka Corporation, Nature Technology Corporation, and Cell and Gene Therapy Catapult.

Market Segmentation

Market By Application

• Gene Therapy
• Vaccinology

Market By Disease

• Infectious Disease
• Cancer
• Genetic Disorder

Market By End use

• Research Institute
• Biotech Companies

Market By Region

• North America
  • US
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • Rest of EU
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Rest of LA
• Middle East & Africa
  • Saudi
  • UAE
  • Rest of MEA

Would like to place an order or any question, please feel free to contact at  sales@acumenresearchandconsulting.com | +1 407 915 4157

TABLE OF CONTENT

Chapter 1. Industry Overview of Plasmid DNA Manufacturing
1.1 Definition and Scope
1.1.1 Definition of Plasmid DNA Manufacturing
1.1.2 Market Segmentation
1.2 Summary
1.2.1 Market Snapshot
1.3 Global Plasmid DNA Manufacturing Market By Application
1.3.1 Global Plasmid DNA Manufacturing Market Revenue and Growth Rate Comparison By Application (2015-2026)
1.3.2 Gene Therapy
1.3.3 Vaccinology
1.4 Global Plasmid DNA Manufacturing Market By Disease
1.4.1 Global Plasmid DNA Manufacturing Market Revenue and Growth Rate Comparison By Disease (2015-2026)
1.4.2 Infectious Disease
1.4.3 Genetic Disorders
1.4.4 Cancer
1.5 Global Plasmid DNA Manufacturing Market By End Use
1.5.1 Global Plasmid DNA Manufacturing Market Revenue and Growth Rate Comparison By End Use (2015-2026)
1.5.2 Research Institutes
1.5.3 Biotech Companies
1.6 Global Plasmid DNA Manufacturing Market by Regions
1.6.1 Global Plasmid DNA Manufacturing Market Size and Growth Rate Comparison by Regions (2015-2026)
1.6.2 North America Plasmid DNA Manufacturing Market Revenue And Growth Rate (2015-2026)
1.6.3 Europe Plasmid DNA Manufacturing Market Revenue And Growth Rate (2015-2026)
1.6.4 Asia-Pacific Plasmid DNA Manufacturing Market Revenue And Growth Rate (2015-2026)
1.6.5 Latin America Plasmid DNA Manufacturing Market Revenue And Growth Rate (2015-2026)
1.6.6 Middle East & Africa Plasmid DNA Manufacturing Market Revenue And Growth Rate (2015-2026)

Chapter 2. Market Dynamics and Competition Analysis
2.1 Market Drivers
2.2 Restraints and Challenges
2.3 Growth Opportunities
2.4 Porter’s Five Forces Analysis
2.4.1 Low Bargaining Power of Suppliers
2.4.2 Medium Bargaining Power of Buyers
2.4.3 High Threat of Substitute
2.4.4 Low Threat of New Entrants
2.4.5 High Degree of Competition
2.5 Value Chain Analysis
2.6 Cost structure Analysis
2.6.1 Raw Material and Suppliers
2.6.2 Proportion of Manufacturing Cost Structure
2.6.2.1 Raw Material
2.6.2.2 Labor Cost
2.6.2.3 Manufacturing Expense
2.7 Regulatory Compliance
2.8 Competitive Landscape, 2018
2.8.1 Player Positioning Analysis
2.8.2 Key Strategies Adopted By Leading Players

Chapter 3. Manufacturing Plant Analysis
3.1 Revenue and Commercial Date of Global Plasmid DNA Manufacturing Major Manufacturers in 2018
3.2 Manufacturing Plants Distribution of Global Plasmid DNA Manufacturing Major Manufacturers in 2018

Chapter 4. Plasmid DNA Manufacturing Market By Application
4.1 Global Plasmid DNA Manufacturing Revenue by Application
4.2 Gene Therapy
4.2.1 Market Revenue and Growth Rate, 2015 – 2026 (US$ Million)
4.2.2 Market Revenue and Forecast, By Region, 2015 – 2026 (US$ Million)
4.3 Vaccinology
4.3.1 Market Revenue and Growth Rate, 2015 – 2026 (US$ Million)
4.3.2 Market Revenue and Forecast, By Region, 2015 – 2026 (US$ Million)

Chapter 5. Plasmid DNA Manufacturing Market By Disease
5.1 Global Plasmid DNA Manufacturing Revenue by Disease
5.2 Infectious Disease
5.2.1 Market Revenue and Growth Rate, 2015 – 2026 (US$Mn)
5.2.2 Market Revenue and Forecast, By Region, 2015 – 2026 (US$Mn)
5.3 Genetic Disorders
5.3.1 Market Revenue and Growth Rate, 2015 – 2026 (US$Mn)
5.3.2 Market Revenue and Forecast, By Region, 2015 – 2026 (US$Mn)
5.4 Cancer
5.4.1 Market Revenue and Growth Rate, 2015 – 2026 (US$Mn)
5.4.2 Market Revenue and Forecast, By Region, 2015 – 2026 (US$Mn)

Chapter 6. Plasmid DNA Manufacturing Market By End Use
6.1 Global Plasmid DNA Manufacturing Revenue by End Use
6.2 Research Institutes
6.2.1 Market Revenue and Growth Rate, 2015 – 2026 (US$Mn)
6.2.2 Market Revenue and Forecast, By Region, 2015 – 2026 (US$Mn)
6.3 Biotech Companies
6.3.1 Market Revenue and Growth Rate, 2015 – 2026 (US$Mn)
6.3.2 Market Revenue and Forecast, By Region, 2015 – 2026 (US$Mn)

Chapter 7. North America Plasmid DNA Manufacturing Market By Country
7.1 North America Plasmid DNA Manufacturing Market Revenue and Growth Rate, 2015 – 2026 (US$ Million)
7.2 North America Plasmid DNA Manufacturing Market Revenue Share, by Country, 2018 (%)
7.3 U.S.
7.3.1 U.S. Plasmid DNA Manufacturing Market Revenue and Forecast By Application, 2015 – 2026 (US$ Million)
7.3.2 U.S. Plasmid DNA Manufacturing Market Revenue and Forecast By Disease, 2015 – 2026 (US$ Million)
7.3.3 U.S. Plasmid DNA Manufacturing Market Revenue and Forecast By End Use, 2015 – 2026 (US$ Million)
7.4 Canada
7.4.1 Canada Plasmid DNA Manufacturing Market Revenue and Forecast By Application, 2015 – 2026 (US$ Million)
7.4.2 Canada Plasmid DNA Manufacturing Market Revenue and Forecast By Disease, 2015 – 2026 (US$ Million)
7.4.3 Canada Plasmid DNA Manufacturing Market Revenue and Forecast By End Use, 2015 – 2026 (US$ Million)

Chapter 8. Europe Plasmid DNA Manufacturing Market By Country (8)
8.1 Europe Plasmid DNA Manufacturing Market Revenue and Growth Rate, 2015 – 2026 (US$ Million)
8.2 Europe Plasmid DNA Manufacturing Market Revenue Share, By Country, 2018 (%)
8.3 UK
8.3.1 UK Plasmid DNA Manufacturing Market Revenue and Forecast By Application, 2015 – 2026 (US$ Million)
8.3.2 UK Plasmid DNA Manufacturing Market Revenue and Forecast By Disease, 2015 – 2026 (US$ Million)
8.3.3 UK Plasmid DNA Manufacturing Market Revenue and Forecast By End Use, 2015 – 2026 (US$ Million)
8.4 Germany
8.4.1 Germany Plasmid DNA Manufacturing Market Revenue and Forecast By Application, 2015 – 2026 (US$ Million)
8.4.2 Germany Plasmid DNA Manufacturing Market Revenue and Forecast By Disease, 2015 – 2026 (US$ Million)
8.4.3 Germany Plasmid DNA Manufacturing Market Revenue and Forecast By End Use, 2015 – 2026 (US$ Million)
8.5 France
8.5.1 France Plasmid DNA Manufacturing Market Revenue and Forecast By Application, 2015 – 2026 (US$ Million)
8.5.2 France Plasmid DNA Manufacturing Market Revenue and Forecast By Disease, 2015 – 2026 (US$ Million)
8.5.3 France Plasmid DNA Manufacturing Market Revenue and Forecast By End Use, 2015 – 2026 (US$ Million)
8.6 Spain
8.6.1 Spain Plasmid DNA Manufacturing Market Revenue and Forecast By Application, 2015 – 2026 (US$ Million)
8.6.2 Spain Plasmid DNA Manufacturing Market Revenue and Forecast By Disease, 2015 – 2026 (US$ Million)
8.6.3 Spain Plasmid DNA Manufacturing Market Revenue and Forecast By End Use, 2015 – 2026 (US$ Million)
8.7 Italy
8.7.1 Italy Plasmid DNA Manufacturing Market Revenue and Forecast By Application, 2015 – 2026 (US$ Million)
8.7.2 Italy Plasmid DNA Manufacturing Market Revenue and Forecast By Disease, 2015 – 2026 (US$ Million)
8.7.3 Italy Plasmid DNA Manufacturing Market Revenue and Forecast By End Use, 2015 – 2026 (US$ Million)
8.8 Rest of Europe
8.8.1 Rest of Europe Plasmid DNA Manufacturing Market Revenue and Forecast By Application, 2015 – 2026 (US$ Million)
8.8.2 Rest of Europe Plasmid DNA Manufacturing Market Revenue and Forecast By Disease, 2015 – 2026 (US$ Million)
8.8.3 Rest of Europe Plasmid DNA Manufacturing Market Revenue and Forecast By End Use, 2015 – 2026 (US$ Million)

Chapter 9. Asia-Pacific Plasmid DNA Manufacturing Market By Country
9.1 Asia-Pacific Plasmid DNA Manufacturing Market Revenue and Growth Rate, 2015 – 2026 (US$ Million)
9.2 Asia-Pacific Plasmid DNA Manufacturing Market Revenue Share Comparison, By Country, 2015 & 2026 (%)
9.3 China
9.3.1 China Plasmid DNA Manufacturing Market Revenue and Forecast By Application, 2015 – 2026 (US$ Million)
9.3.2 China Plasmid DNA Manufacturing Market Revenue and Forecast By Disease, 2015 – 2026 (US$ Million)
9.3.3 China Plasmid DNA Manufacturing Market Revenue and Forecast By End Use, 2015 – 2026 (US$ Million)
9.4 Japan
9.4.1 Japan Plasmid DNA Manufacturing Market Revenue and Forecast By Application, 2015 – 2026 (US$ Million)
9.4.2 Japan Plasmid DNA Manufacturing Market Revenue and Forecast By Disease, 2015 – 2026 (US$ Million)
9.4.3 Japan Plasmid DNA Manufacturing Market Revenue and Forecast By End Use, 2015 – 2026 (US$ Million)
9.5 India
9.5.1 India Plasmid DNA Manufacturing Market Revenue and Forecast By Application, 2015 – 2026 (US$ Million)
9.5.2 India Plasmid DNA Manufacturing Market Revenue and Forecast By Disease, 2015 – 2026 (US$ Million)
9.5.3 India Plasmid DNA Manufacturing Market Revenue and Forecast By End Use, 2015 – 2026 (US$ Million)
9.6 Australia
9.6.1 Australia Plasmid DNA Manufacturing Market Revenue and Forecast By Application, 2015 – 2026 (US$ Million)
9.6.2 Australia Plasmid DNA Manufacturing Market Revenue and Forecast By Disease, 2015 – 2026 (US$ Million)
9.6.3 Australia Plasmid DNA Manufacturing Market Revenue and Forecast By End Use, 2015 – 2026 (US$ Million)
9.7 South Korea
9.7.1 South Korea Plasmid DNA Manufacturing Market Revenue and Forecast By Application, 2015 – 2026 (US$ Million)
9.7.2 South Korea Plasmid DNA Manufacturing Market Revenue and Forecast By Disease, 2015 – 2026 (US$ Million)
9.7.3 South Korea Plasmid DNA Manufacturing Market Revenue and Forecast By End Use, 2015 – 2026 (US$ Million)
9.8 Rest of Asia-Pacific
9.8.1 Rest of Asia-Pacific Plasmid DNA Manufacturing Market Revenue and Forecast By Application, 2015 – 2026 (US$ Million)
9.8.2 Rest of Asia-Pacific Plasmid DNA Manufacturing Market Revenue and Forecast By Disease, 2015 – 2026 (US$ Million)
9.8.3 Rest of Asia-Pacific Plasmid DNA Manufacturing Market Revenue and Forecast By End Use, 2015 – 2026 (US$ Million)

Chapter 10. Latin America Plasmid DNA Manufacturing Market By Country
10.1 Latin America Plasmid DNA Manufacturing Market Revenue and Growth Rate, 2015 – 2026 (US$ Million)
10.2 Latin America Plasmid DNA Manufacturing Market Revenue Share, by Country, 2018 (%)
10.3 Brazil
10.3.1 Brazil Plasmid DNA Manufacturing Market Revenue and Forecast By Application, 2015 – 2026 (US$ Million)
10.3.2 Brazil Plasmid DNA Manufacturing Market Revenue and Forecast By Disease, 2015 – 2026 (US$ Million)
10.3.3 Brazil Plasmid DNA Manufacturing Market Revenue and Forecast By End Use, 2015 – 2026 (US$ Million)
10.4 Mexico
10.4.1 Mexico Plasmid DNA Manufacturing Market Revenue and Forecast By Application, 2015 – 2026 (US$ Million)
10.4.2 Mexico Plasmid DNA Manufacturing Market Revenue and Forecast By Disease, 2015 – 2026 (US$ Million)
10.4.3 Mexico Plasmid DNA Manufacturing Market Revenue and Forecast By End Use, 2015 – 2026 (US$ Million)
10.5 Rest of Latin America
10.5.1 Rest of Latin America Plasmid DNA Manufacturing Market Revenue and Forecast By Application, 2015 – 2026 (US$ Million)
10.5.2 Rest of Latin America Plasmid DNA Manufacturing Market Revenue and Forecast By Disease, 2015 – 2026 (US$ Million)
10.5.3 Rest of Latin America Plasmid DNA Manufacturing Market Revenue and Forecast By End Use, 2015 – 2026 (US$ Million)

Chapter 11. Middle East & Africa Plasmid DNA Manufacturing Market By Country
11.1 Middle East & Africa Plasmid DNA Manufacturing Market Revenue and Growth Rate, 2015 – 2026 (US$ Million)
11.2 Middle East & Africa Plasmid DNA Manufacturing Market Revenue Share Comparison, By Countries, 2018 (%)
11.3 Saudi Arabia
11.3.1 Saudi Arabia Plasmid DNA Manufacturing Market Revenue and Forecast By Application, 2015 – 2026 (US$ Million)
11.3.2 Saudi Arabia Plasmid DNA Manufacturing Market Revenue and Forecast By Disease, 2015 – 2026 (US$ Million)
11.3.3 Saudi Arabia Plasmid DNA Manufacturing Market Revenue and Forecast By End Use, 2015 – 2026 (US$ Million)
11.4 UAE
11.4.1 UAE Plasmid DNA Manufacturing Market Revenue and Forecast By Application, 2015 – 2026 (US$ Million)
11.4.2 UAE Plasmid DNA Manufacturing Market Revenue and Forecast By Disease, 2015 – 2026 (US$ Million)
11.4.3 UAE Plasmid DNA Manufacturing Market Revenue and Forecast By End Use, 2015 – 2026 (US$ Million)
11.5 Rest of Middle East & Africa
11.5.1 Rest of Middle East & Africa Plasmid DNA Manufacturing Market Revenue and Forecast By Application, 2015 – 2026 (US$ Million)
11.5.2 Rest of Middle East & Africa Plasmid DNA Manufacturing Market Revenue and Forecast By Disease, 2015 – 2026 (US$ Million)
11.5.3 Rest of Middle East & Africa Plasmid DNA Manufacturing Market Revenue and Forecast By End Use, 2015 – 2026 (US$ Million)

Chapter 12. Major Manufacturers Analysis of Plasmid DNA
12.1 Cobra Biologics Limited
12.1.1 Business Overview
12.1.2 Company Profile
12.1.3 Cobra Biologics Limited 2018 Financial Analysis
12.1.4 Cobra Biologics Limited 2018 Plasmid DNA Business Region Distribution Analysis
12.1.5 Product Segment
12.1.6 Marketing Strategy and Recent Development
12.2 Novasep Inc.
12.2.1 Business Overview
12.2.2 Company Profile
12.2.3 Novasep Inc. 2018 Financial Analysis
12.2.4 Novasep Inc. 2018 Plasmid DNA Business Region Distribution Analysis
12.2.5 Product Segment
12.2.6 Marketing Strategy and Recent Development
12.3 Spark Therapeutics, Inc.
12.3.1 Business Overview
12.3.2 Company Profile
12.3.3 Spark Therapeutics, Inc. 2018 Financial Analysis
12.3.4 Spark Therapeutics, Inc. 2018 Plasmid DNA Business Region Distribution Analysis
12.3.5 Product Segment
12.3.6 Marketing Strategy and Recent Development
12.4 FUJIFILM Diosynth Biotechnologies Inc.
12.4.1 Business Overview
12.4.2 Company Profile
12.4.3 FUJIFILM Diosynth Biotechnologies Inc. 2018 Financial Analysis
12.4.4 FUJIFILM Diosynth Biotechnologies Inc. 2018 Plasmid DNA Business Region Distribution Analysis
12.4.5 Product Segment
12.4.6 Marketing Strategy and Recent Development
12.5 Cell and Gene Therapy Catapult
12.5.1 Business Overview
12.5.2 Company Profile
12.5.3 Cell and Gene Therapy Catapult 2018 Plasmid DNA Sales, Ex-factory Price, Revenue, Gross Margin Analysis
12.5.4 Cell and Gene Therapy Catapult 2018 Plasmid DNA Business Region Distribution Analysis
12.5.5 Product Segment
12.5.6 Marketing Strategy and Recent Development
12.6 Kaneka Eurogentec S.A (KANEKA)
12.6.1 Business Overview
12.6.2 Company Profile
12.6.3 Kaneka Eurogentec S.A 2018 Plasmid DNA Sales, Ex-factory Price, Revenue, Gross Margin Analysis
12.6.4 Kaneka Eurogentec S.A 2018 Plasmid DNA Business Region Distribution Analysis
12.6.5 Product Segment
12.6.6 Marketing Strategy and Recent Development
12.7 UniQure N.V.
12.7.1 Business Overview
12.7.2 Company Profile
12.7.3 uniQure N.V. Financial Analysis, 2019
12.7.4 uniQure N.V Plasmid DNA Business Region Distribution Analysis, 2019
12.7.5 Product Segment
12.7.6 Marketing Strategy and Recent Development
12.8 Lonza
12.8.1 Business Overview
12.8.2 Company Profile
12.8.3 Lonza Financial Analysis, 2018
12.8.4 Lonza Plasmid DNA Business Region Distribution Analysis, 2018
12.8.5 Product Segment
12.8.6 Marketing Strategy and Recent Development
12.9 Merk KgaA
12.9.1 Business Overview
12.9.2 Company Profile
12.9.3 Merk KgaA Financial Analysis, 2018
12.9.4 Merk KgaA Plasmid DNA Business Region Distribution Analysis, 2018
12.9.5 Product Segment
12.9.6 Marketing Strategy and Recent Development

Chapter 13. Research Approach
13.1 Methodology
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources

The report is readily available and can be dispatched immediately after payment confirmation.

Buy this premium research report@ https://www.acumenresearchandconsulting.com/buy-now/0/1583

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.